CMPX
Compass Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.38
+0.42%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+17.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Apr 30, 2026 | Lerner Neil · officer: Chief Accounting Officer | Purchase | 15,000 | $1.89 |
| Apr 30, 2026 | Anderman Jonathan · officer: General Counsel | Purchase | 25,000 | $1.89 |
| Apr 29, 2026 | Lerner Neil · officer: Chief Accounting Officer | A-Award | 15,000 | $1.89 |
| Apr 29, 2026 | Anderman Jonathan · officer: General Counsel | A-Award | 25,000 | $1.89 |
| Feb 10, 2026 | Schuetz Thomas J. · director, officer: CHIEF EXECUTIVE OFFICER | F-InKind | 36,687 | $6.52 |
| Jan 12, 2026 | Schuetz Thomas J. · director, officer: CHIEF EXECUTIVE OFFICER | F-InKind | 46,777 | $5.35 |
| Jan 5, 2026 | Schuetz Thomas J. · director, officer: CEO | A-Award | 2,000,000 | $5.17 |
| Jan 5, 2026 | Prasad Arjun · officer: Chief Commercial Officer | A-Award | 1,000,000 | $5.17 |
| Jan 5, 2026 | LINDAHL RICHARD S · director | A-Award | 90,000 | $5.17 |
| Jan 5, 2026 | Chiniara Ellen · director | A-Award | 90,000 | $5.17 |
| Jan 5, 2026 | Lerner Neil · officer: Chief Accounting Officer | A-Award | 435,000 | $5.17 |
| Jan 5, 2026 | Lerner Neil · officer: Chief Accounting Officer | A-Award | 62,500 | $5.17 |
| Jan 5, 2026 | GRAY MARY ANN · director | A-Award | 90,000 | $5.17 |
| Jan 5, 2026 | Boylan James P · director | A-Award | 90,000 | $5.17 |
| Jan 5, 2026 | GORDON CARL L · director | A-Award | 90,000 | $5.17 |
| Jan 5, 2026 | Ferneau Philip · director | A-Award | 90,000 | $5.17 |
| Jan 5, 2026 | Anderman Jonathan · officer: General Counsel | A-Award | 720,000 | $5.17 |
| Jan 5, 2026 | Anderman Jonathan · officer: General Counsel | A-Award | 150,000 | $5.17 |
| Jan 5, 2026 | Shin Barry · officer: CFO | A-Award | 670,000 | $5.17 |
| Jan 5, 2026 | Schuetz Thomas J. · director, officer: CEO | A-Award | 250,000 | $5.17 |
| Jan 5, 2026 | Shin Barry · officer: CFO | A-Award | 125,000 | $5.17 |
| Jan 5, 2026 | Sirard Cynthia · officer: Chief Medical Officer | A-Award | 1,000,000 | $5.17 |
| Nov 18, 2025 | Schuetz Thomas J. · director, officer: CHIEF EXECUTIVE OFFICER | F-InKind | 44,025 | $4.83 |
| May 27, 2025 | Schuetz Thomas J. · director, officer: CHIEF EXECUTIVE OFFICER | Purchase | 10,000 | $2.11 |
| Apr 11, 2025 | ORBIMED ADVISORS LLC · director, 10 percent owner: | Sale | 3,571,428 | $1.59 |
| Apr 11, 2025 | GORDON CARL L · director, 10 percent owner: | Sale | 3,571,428 | $1.59 |
| Apr 8, 2025 | Anderman Jonathan · officer: Gen Counsel & Corporate Sec | Purchase | 20,000 | $1.54 |
| Apr 8, 2025 | Lerner Neil · officer: CHIEF ACCOUNTING OFFICER | Purchase | 20,000 | $1.42 |
| Feb 13, 2025 | GRAY MARY ANN · director | A-Award | 40,000 | $3.65 |
| Feb 13, 2025 | Ferneau Philip · director | A-Award | 40,000 | $3.65 |
Institutional positioning
13F filings over the trailing two quarters
New 54Increased 75Reduced 51Sold out 200
| Filer | Action | Shares | Filed |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | Unchanged | 16,790,809 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 15,219,994 | May 15, 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Increased | 14,307,379 | May 15, 2026 |
| VIVO CAPITAL, LLC | Unchanged | 9,545,466 | May 20, 2026 |
| BLACKROCK, INC. | Increased | 9,506,080 | May 13, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Increased | 8,486,500 | May 15, 2026 |
| ENAVATE SCIENCES GP, LLC | Unchanged | 7,788,150 | May 15, 2026 |
| BVF INC/IL | Unchanged | 7,764,842 | May 15, 2026 |
| STATE STREET CORP | Increased | 6,694,976 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 6,037,175 | May 15, 2026 |
| RTW INVESTMENTS, LP | Increased | 4,186,599 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 3,709,974 | Sep 2, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Unchanged | 3,606,000 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 3,565,770 | May 15, 2026 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | Reduced | 3,305,308 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Apr 30, 2026